Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...
Eli Lilly announced Wednesday it will invest another $4.5 billion into a new facility at the states controversial LEAP ...
Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...
Eli Lilly and Company will invest an additional $4.5 billion in Boone County to create a new center for advanced ...
Eli Lilly is pouring another $4.5 billion into expanding manufacturing and development as the drugmaker rakes in billions ...
Eli Lilly & Co. is pouring $4.5 billion into a new manufacturing plant in Indiana to make drugs for future clinical trials, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback